Comparison of salvage radical prostatectomy vs. salvage ablation therapy for biopsy-proven radio-recurrent localized prostate cancer Journal Article


Authors: McPherson, V.; Nair, S. M.; Tin, A. L.; Dewar, M.; Siddiqui, K.; Sjoberg, D. D.; Vickers, A. J.; Eastham, J.; Chin, J. L.
Article Title: Comparison of salvage radical prostatectomy vs. salvage ablation therapy for biopsy-proven radio-recurrent localized prostate cancer
Abstract: Introduction: Radiation therapy for prostate cancer is associated with a 15–20% five-year recurrence rate. Patients with recurrence in the prostate only are candidates for salvage local therapies, however, there is no consensus on modality. This study uses registries at Memorial Sloan Kettering Cancer Center (MSKCC) and University of Western Ontario (UWO) to compare the oncologic outcomes of salvage radical prostatectomy (SRP) and salvage ablation (SA). Methods: A total of 444 patients were available for analysis. Due to intergroup differences, propensity score methodology was used and identified 378 patients with more comparable pre-salvage PSA, Gleason score, and primary radiation treatment. Patients underwent SRP at MSKCC and SA at UWO. Results: Of the 378 patients, 48 died of disease, with a 6.0-year median (interquartile range [IQR] 3.0, 9.7) followup among survivors; 88 developed metastases, with a median 4.6-year (IQR 2.3, 7.9) followup among metastasis-free survivors. There was a non-significantly higher rate of cancer-specific (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.51, 2.06, p=0.9) and improved metastasis-free survival (HR 0.71, 95% CI 0.44, 1.13, p=0.15) among patients undergoing SA compared to patients undergoing SRP. There were 143 patients who received hormonal therapy, with higher rates of androgen deprivation therapy (ADT) in SA (HR 1.42, 95% CI 0.97, 2.08, p=0.068), although this did not meet conventional levels of significance. Conclusions: This propensity score analysis of salvage therapy for radio-recurrent prostate cancer identified no statistically significant differences in oncologic outcome between SRP and SA; however, there was evidence of a lower risk of ADT in the cohort undergoing SRP. Given they are both potentially curative therapies, these treatments are viable options for men with clinically localized, radio-recurrent prostate cancer rather than ADT alone. Future research may further elucidate subpopulations that may be more amenable to either SRP or SA. © 2024 Canadian Urological Association. All rights reserved.
Keywords: adult; controlled study; cancer surgery; major clinical study; cancer recurrence; salvage therapy; comparative study; outcome assessment; follow up; tumor biopsy; cancer survivor; cancer hormone therapy; prostate cancer; gleason score; cancer specific survival; radical prostatectomy; androgen deprivation therapy; ablation therapy; propensity score; metastasis free survival; human; male; article
Journal Title: CUAJ-Canadian Urological Association Journal
Volume: 18
Issue: 2
ISSN: 1911-6470
Publisher: Canadian Urological Association  
Date Published: 2024-02-01
Start Page: 41
End Page: 46
Language: English
DOI: 10.5489/cuaj.8373
PROVIDER: scopus
PUBMED: 37931280
PMCID: PMC10841561
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew J Vickers
    880 Vickers
  2. Daniel D. Sjoberg
    234 Sjoberg
  3. James Eastham
    537 Eastham
  4. Amy Lam Ling Tin
    114 Tin